• OPEN AN ACCOUNT
Indian Indices
Nifty
22,302.50 -140.20
(-0.62%)
Sensex
73,511.85 -383.69
( -0.52%)
Bank Nifty
48,285.35 -609.95
( -1.25%)
Nifty IT
33,473.00 255.90
( 0.77%)
Global Indices
Nasdaq
16,332.56 -16.69
(-0.10%)
Dow Jones
38,884.26 31.99
(0.08%)
Hang Seng
18,479.37 -98.93
(-0.53%)
Nikkei 225
38,835.10 599.03
(1.57%)
Forex
USD-INR
83.38 -0.05
(-0.06%)
EUR-INR
89.73 0.36
(0.40%)
GBP-INR
104.61 0.13
(0.13%)
JPY-INR
0.54 0.01
(1.03%)

EQUITY - MARKET SCREENER

Bajaj Healthcare Ltd
Industry :  Pharmaceuticals - Indian - Bulk Drugs & Formln
BSE Code
ISIN Demat
Book Value()
539872
INE411U01027
114.5518581
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
BAJAJHCARE
29.7
855.69
EPS(TTM)
Face Value()
Div & Yield %
10.44
5
0.32
 

Bajaj Healthcare Ltd
Bajaj Healthcare enters into CDMO agreement for 15 APIs
Feb 28,2024
Bajaj Healthcare (BHL) announced that it has entered into a definitive CDMO agreement with esteemed UK/EU based customers for the supply of 15 Active Pharmaceutical Ingredient (APIs).

Under this agreement, BHL will undertake the development and supply of these molecules, which will be exclusively manufactured for its clientele. These APIs encompass a diverse range of compounds, including off-patent generics and molecules soon to be off-patent. The CDMO agreement will be executed through its in-house R&D and manufacturing capacities at Savli Vadodara, Gujarat.